论文部分内容阅读
近年认为5-HT在增加外周血管阻力方面起重要作用。ketanserin是一个选择性5-HT_2受体拮抗药,并因对突触后膜的α_1受体有作用而具有抗交感活性,可用于治疗原发性高血压。本文报道了ketanserin 在两组轻至中度高血压病人中进行的单盲及安慰剂对照的临床研究。28名轻至中度高血压病人,年龄在43～75岁(中位年龄58岁),男性15名,女性13
In recent years, 5-HT is considered to play an important role in increasing peripheral vascular resistance. ketanserin is a selective 5-HT 2 receptor antagonist and has anti-sympathetic activity due to its effect on the α 1 receptor of the postsynaptic membrane for the treatment of essential hypertension. This article reports the single-blind, placebo-controlled clinical trial of ketanserin in two groups of patients with mild-to-moderate hypertension. 28 mild-to-moderate hypertensive patients, aged 43 to 75 years (median age 58 years), 15 males and 13 females